ストックスクリーナーアプリを入手
41.26
3.17%
1.1939
前日終値:
$40.07
開ける：
$40.37
24時間の取引高:
43,161
Relative Volume:
0.11
時価総額：
$1.20B
収益：
$219.79M
当期純損益:
$-57.47M
株価収益率:
-19.19
EPS:
-2.15
ネットキャッシュフロー:
$-19.25M
1週間 パフォーマンス:
+6.27%
1か月 パフォーマンス:
+6.99%
6か月 パフォーマンス:
+112.44%
1年 パフォーマンス:
+28.50%
1日の値動き範囲:
$39.99
$41.34
1週間の範囲:
$37.29
$41.34
52週間の値動き範囲:
$14.59
$42.17
Castle Biosciences Inc Stock (CSTL) Company Profile
名前
Castle Biosciences Inc
セクター
電話
866-788-9007
住所
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
41.25 | 1.17B | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
621.33 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.64 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.49 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.92 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
245.81 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-04-30 | 開始されました | Lake Street | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | BTIG Research | Buy |
| 2019-08-19 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Castle Biosciences Inc (CSTL) 最新ニュース
What drives Castle Biosciences Inc stock priceWeekly Market Snapshot & Affordable Trading Plans - earlytimes.in
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares - MarketBeat
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus - Yahoo Finance
Is Castle Biosciences Inc. stock vulnerable to regulatory risksHealthcare Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
Breakouts Watch: Why Castle Biosciences Inc. stock is considered a top pick2025 Sector Review & Real-Time Volume Triggers - moha.gov.vn
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - sharewise.com
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
Castle Biosciences stock hits 52-week high at 40.66 USD - Investing.com
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Castle Biosciences stock hits 52-week high at 40.66 USD By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Castle Biosciences Inc. stock a top momentum playWeekly Investment Recap & Safe Swing Trade Setup Alerts - Улправда
Why Castle Biosciences Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Castle Biosciences Inc. stock positioned for digital transformationJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - Улправда
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares - MarketBeat
Why retail investors favor Castle Biosciences Inc. stockPortfolio Value Summary & Fast Momentum Entry Tips - Улправда
Can Castle Biosciences Inc. stock continue upward trend2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Castle Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - TradingView — Track All Markets
Can Castle Biosciences Inc. stock maintain operating marginsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is Castle Biosciences Inc. stock a buy before product launchesMarket Trend Review & Real-Time Volume Analysis - Улправда
Is Castle Biosciences Inc. stock trading at a premium valuationJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
COO Oelschlager Files To Sell 14,888 Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CEO reports stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Reveals Enhanced Predictive Method for Uveal Melanoma Outcomes - GuruFocus
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study - Investing.com
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination - Quiver Quantitative
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewswire
CFO Stokes Sells 4,496 ($168.4K) Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CCO reports sale of 13,200 shares - Stock Titan
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at BTIG Research - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Bought by Braidwell LP - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Castle Biosciences (CSTL) Highlights Breakthrough in Barrett's E - GuruFocus
Castle Biosciences Announces Publication of Study Confirming TissueCypher® Test's Efficacy in Risk Stratification for Barrett's Esophagus Patients - Quiver Quantitative
BTIG Maintains Castle Biosciences (CSTL) Buy Recommendation - Nasdaq
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer - GlobeNewswire
Castle Biosciences (NASDAQ: CSTL) CCO reports RSU settlements and share disposals - Stock Titan
Castle Biosciences Inc (CSTL) 財務データ
収益
当期純利益
現金流量
EPS
1.56%
0.67%
大文字化:
|
ボリューム (24 時間):